OM:VITR - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4,215	731	970	1,114	3
12/31/2025	3,970	674	874	1,008	4
12/31/2024	3,648	569	787	911	4
3/31/2024	3,499	-3,836	655	795	N/A
12/31/2023	3,512	-3,851	638	757	N/A
9/30/2023	3,462	402	650	752	N/A
6/30/2023	3,412	388	652	738	N/A
3/31/2023	3,336	412	631	706	N/A
12/31/2022	3,234	394	549	636	N/A
9/30/2022	2,893	353	366	470	N/A
6/30/2022	2,501	349	288	377	N/A
3/31/2022	2,054	305	249	331	N/A
12/31/2021	1,681	341	321	384	N/A
9/30/2021	1,549	415	525	555	N/A
6/30/2021	1,464	399	515	545	N/A
3/31/2021	1,291	325	455	479	N/A
12/31/2020	1,246	287	336	356	N/A
9/30/2020	1,273	276	278	303	N/A
6/30/2020	1,331	294	332	361	N/A
3/31/2020	1,502	377	315	399	N/A
12/31/2019	1,480	383	326	413	N/A
9/30/2019	1,391	371	210	412	N/A
6/30/2019	1,297	339	93	344	N/A
3/31/2019	1,199	324	199	341	N/A
12/31/2018	1,151	310	169	349	N/A
9/30/2018	1,102	294	286	343	N/A
6/30/2018	1,064	284	337	341	N/A
3/31/2018	1,066	276	266	321	N/A
12/31/2017	1,046	264	N/A	312	N/A
9/30/2017	1,026	255	N/A	281	N/A
6/30/2017	991	234	N/A	243	N/A
3/31/2017	913	211	N/A	204	N/A
12/31/2016	856	190	N/A	181	N/A
9/30/2016	804	188	N/A	197	N/A
6/30/2016	771	196	N/A	210	N/A
3/31/2016	747	186	N/A	196	N/A
12/31/2015	722	183	N/A	194	N/A
9/30/2015	660	154	N/A	138	N/A
6/30/2015	609	137	N/A	132	N/A
3/31/2015	554	122	N/A	130	N/A
12/31/2014	511	109	N/A	146	N/A
9/30/2014	497	96	N/A	145	N/A
6/30/2014	481	77	N/A	121	N/A
3/31/2014	467	67	N/A	111	N/A
12/31/2013	453	56	N/A	106	N/A
9/30/2013	427	41	N/A	88	N/A
6/30/2013	401	32	N/A	64	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VITRは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: VITR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: VITR今後 3 年以内に収益を上げることが予想されます。

収益対市場: VITRの収益 ( 7.1% ) Swedish市場 ( 2% ) よりも速いペースで成長すると予測されています。

高い収益成長: VITRの収益 ( 7.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VITRの自己資本利益率は、3年後には低くなると予測されています ( 5 %)。

Vitrolife 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Price target decreased by 8.9% to kr257

Consensus EPS estimates fall by 16%

Price target decreased by 7.4% to kr292

Price target decreased to kr260

Price target decreased to kr307

Recent updates

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Now 22% undervalued

Dividend increased to kr1.00

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Investor sentiment improves as stock rises 21%

Price target decreased by 8.9% to kr257

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife (STO:VITR) Could Easily Take On More Debt

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought kr335k worth of stock

Consensus EPS estimates fall by 16%

Price target decreased by 7.4% to kr292

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 15%

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

Chief Financial Officer recently bought kr535k worth of stock

Chief Financial Officer recently bought kr535k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Is Vitrolife (STO:VITR) A Risky Investment?

Price target decreased to kr260

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Investor sentiment improved over the past week

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Vitrolife AB (publ) Announces Election Committee Appointments

Price target decreased to kr307

Now 30% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Is Vitrolife (STO:VITR) A Risky Investment?

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Chief Financial Officer recently bought kr496k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to kr448

Upcoming dividend of kr0.80 per share

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Vitrolife AB (Publ) Proposes Dividend

Consensus forecasts updated

Price target decreased to kr498

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vitrolife AB (Publ) Proposes Dividend